Vγ9Vδ2T cells show broader antitumor cytotoxicity than CD4+ and CD8+ T lymphocytes, and they are able to directly target and kill cancer cells via surface receptors (NKG2D) and cytokines (IFN-γ). The gene discussed is KLRK1; the disease is cancer.